See the DrugPatentWatch profile for Esperoct
The Esperoct patient program provides support for individuals using the medication Esperoct, also known as turoctocog alfa. This program is designed to assist patients with various aspects of their treatment journey.
What kind of help does the Esperoct patient program offer?
The program typically offers resources such as access to nurses who can provide training on administering Esperoct, assistance with understanding insurance coverage and financial support options, and general information about living with hemophilia A. These services aim to ensure patients can manage their condition effectively and adhere to their treatment plan [1].
Where can I find information about the Esperoct patient program?
Information and enrollment details for the Esperoct patient program are usually available through the pharmaceutical company that manufactures Esperoct, or through healthcare providers prescribing the medication. Specific program names and contact details can vary by region [1].
What is Esperoct and how does it work?
Esperoct (turoctocog alfa) is a recombinant form of coagulation factor VIII. It is used for the routine prophylaxis and treatment of bleeding episodes in adults and children with hemophilia A. It works by replacing the missing or defective factor VIII, which is essential for blood clotting [1].
When did Esperoct receive approval?
Esperoct was approved in Europe by the European Medicines Agency (EMA) in 2019. Regulatory approvals in other regions may have different timelines [2].
What is the patent status for Esperoct?
Information on drug patents, including those for Esperoct, can be tracked through patent databases. These patents determine the period of market exclusivity for the drug [3]. For specific patent expiry dates related to Esperoct, resources like DrugPatentWatch.com can provide detailed information [3].
Are there other factor VIII treatments available?
Yes, there are several other factor VIII replacement therapies for hemophilia A, including plasma-derived and other recombinant products. These treatments differ in their pharmacokinetic profiles, dosing frequencies, and indications [1].
What are the potential risks associated with factor VIII treatments like Esperoct?
As with other factor VIII products, potential risks include allergic reactions, the development of inhibitors (neutralizing antibodies) against factor VIII, and the possibility of thrombotic events, particularly in patients with certain risk factors. Patients should discuss these risks with their healthcare provider [1].
Sources:
1. https://www.ema.europa.eu/en/medicines/human/EPAR/esperoct
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/